Selepressin
Investigational — selective V1a medicines that activate their target pathway — not approved.
Ref $ —reference only
SelepressinIn clinical trials · Not yet FDA-approvedWhat it's for
Investigational — selective V1a medicines that activate their target pathway — not approved.
What it's for
Selepressin is an still being studied short-acting selective V1a medicine that turns a receptor signal on.
What it does for the body
Studied as a vasopressor in septic shock aiming for blood-vessel tightening with less V2 water-retention effects. Not approved. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
Selective V1a activating its target pathway increases vascular tone. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Selepressin is still being studied in people. Watch for peer-reviewed trial readouts and regulator decisions — not just social-media summaries.
Studied for (literature interest)
- Heart research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Selepressin — FDA.gov search
- ClinicalTrials.gov search: Selepressin — U.S. clinical trials registry
- Drugs@FDA search: Selepressin — FDA drug database (if approved)
- PubMed search: Selepressin — NCBI PubMed
- PubMed Central search: Selepressin — NCBI PMC
Reference
No ref on file.